Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168620 | 0.86 | HPGD (0.55) | HPGDCYP1A2CYP2D6CYP2C19NPC1 | |
| SCHEMBL25607328 | 0.85 | NPC1 (0.51) | CYP1A2CYP2D6CYP2C19NPC1RAB9A | |
| SCHEMBL24571390 | 0.85 | HPGD (0.53) | HPGDCYP1A2CYP2D6CYP2C19NPC1 | |
| SCHEMBL4159724 | 0.85 | HPGD (0.53) | HPGDCYP1A2CYP2D6CYP2C19NPC1 | |
| SCHEMBL24567577 | 0.85 | HPGD (0.53) | HPGDCYP1A2CYP2D6CYP2C19NPC1 | |
| SCHEMBL15271735 | 0.85 | GLA (0.55) | HPGDCYP1A2CYP2D6CYP2C19NPC1 | |
| SCHEMBL4181155 | 0.84 | HPGD (0.52) | HPGDCYP1A2CYP2D6CYP2C19NPC1 | |
| SCHEMBL24093941 | 0.83 | HPGD (0.51) | HPGDCYP1A2CYP2D6CYP2C19NPC1 | |
| SCHEMBL12126797 | 0.83 | HPGD (0.51) | HPGDCYP1A2CYP2D6CYP2C19NPC1 | |
| SCHEMBL23689650 | 0.82 | MEN1 (0.73) | HPGDCYP1A2CYP2D6CYP2C19RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113227089-B | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors | 吉利德科学公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | NYSNOBIO IRELAND DAC (IE) | 2021-08-12 | — | — | US | disclosed |
| US-20180194771-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-07-12 | — | — | US | disclosed |
| EP-3169662-B1 | SUBSTITUTED VINYL- AND ALKINYL-CYANOCYCLOALKANOLS AND VINYL- AND ALKINYL-CYANOHETEROCYCLOALKANOLS AS AGENTS TO COMBAT ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2018-07-11 | — | — | EP | disclosed |
| US-9884867-B2 | Bicyclic alkyne derivatives and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-06 | — | — | US | disclosed |
| US-9884867-B2 | Bicyclic alkyne derivatives and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-06 | — | — | US | disclosed |
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| EP-2275413-A1 | 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080119468-A1 | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | CCR8, CCR1, CCR3 | HPGD 2003/4885CYP1A2 2414/4885CYP2D6 2186/4885 |
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | HPGD 140/4885CYP1A2 313/4885CYP2D6 325/4885 |
| US-20080119468-A1 | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | HPGD 2348/4885CYP1A2 1001/4885CYP2D6 2612/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | HPGD 283/4885CYP1A2 1682/4885CYP2D6 2336/4885 |
| US-20180194771-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | MAPKAPK2, CAMKK2, MKNK2 | HPGD 3128/4885CYP1A2 3148/4885CYP2D6 4501/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | HPGD 139/4885CYP1A2 324/4885CYP2D6 311/4885 |
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | TP53, RB1, CDK1 | HPGD 2202/4885CYP1A2 4530/4885CYP2D6 4314/4885 |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | CCR8, CCR1, CCR3 | HPGD 2003/4885CYP1A2 2414/4885CYP2D6 2186/4885 |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | HPGD 1224/4885CYP1A2 3729/4885CYP2D6 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.